NCT05437263: An ongoing trial by Priovant Therapeutics, Inc.
This trial is ongoing. It must report results 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05437263 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 31, 2022 |
| Completion date | July 17, 2025 |
| Required reporting date | July 17, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |